0.3233
price down icon40.88%   -0.222
after-market 시간 외 거래: .32 -0.00325 -1.01%
loading
전일 마감가:
$0.5452
열려 있는:
$0.4344
하루 거래량:
10.47M
Relative Volume:
22.24
시가총액:
$28.55M
수익:
-
순이익/손실:
$-60.61M
주가수익비율:
-0.5388
EPS:
-0.6
순현금흐름:
$-22.91M
1주 성능:
-29.63%
1개월 성능:
-31.57%
6개월 성능:
-48.26%
1년 성능:
-78.80%
1일 변동 폭
Value
$0.3198
$0.4344
1주일 범위
Value
$0.3198
$0.565
52주 변동 폭
Value
$0.3198
$1.89

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
명칭
Bioline Rx Ltd Adr
Name
전화
-
Name
주소
-
Name
직원
79
Name
트위터
Name
다음 수익 날짜
2024-12-21
Name
최신 SEC 제출 서류
Name
BLRX's Discussions on Twitter

BLRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BLRX 0.3233 28.55M 0 -60.61M -22.91M -0.60
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2017-05-18 업그레이드 Maxim Group Hold → Buy
2017-02-13 개시 Rodman & Renshaw Buy
2016-08-12 다운그레이드 Maxim Group Buy → Hold
2015-08-17 재확인 Maxim Group Buy
2015-07-27 재확인 ROTH Capital Buy
2015-06-22 개시 JMP Securities Mkt Outperform
모두보기

Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스

pulisher
09:52 AM

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

09:52 AM
pulisher
07:38 AM

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - TipRanks

07:38 AM
pulisher
07:21 AM

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

07:21 AM
pulisher
06:44 AM

SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow

06:44 AM
pulisher
Nov 20, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga

Nov 20, 2024
pulisher
Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024
pulisher
Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024
pulisher
Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024
pulisher
Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024
pulisher
Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024
pulisher
Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024
pulisher
Oct 01, 2024

Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex

Oct 01, 2024
pulisher
Sep 02, 2024

A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

BLRX overperforms with a 0.95 increase in share price - US Post News

Sep 02, 2024
pulisher
Aug 23, 2024

Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research

Aug 23, 2024
pulisher
Aug 19, 2024

BioLineRx Schedules Annual Shareholders Meeting - TipRanks

Aug 19, 2024
pulisher
Aug 16, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex

Aug 16, 2024
pulisher
Aug 16, 2024

BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle

Aug 16, 2024
pulisher
Aug 16, 2024

Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com

Aug 16, 2024
pulisher
Aug 15, 2024

BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks

Aug 15, 2024
pulisher
Aug 15, 2024

Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks

Aug 15, 2024
pulisher
Jul 30, 2024

Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

Jul 30, 2024
pulisher
Jul 30, 2024

Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex

Jul 30, 2024
pulisher
Jul 18, 2024

There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News

Jul 18, 2024
pulisher
Jul 17, 2024

Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News

Jul 17, 2024
pulisher
Jul 11, 2024

BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle

Jul 11, 2024
pulisher
Jul 04, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex

Jul 04, 2024
pulisher
Jun 19, 2024

Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Jun 19, 2024
pulisher
Jun 14, 2024

BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com

Jun 14, 2024
pulisher
Jun 01, 2024

What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register

Jun 01, 2024
pulisher
May 31, 2024

Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News

May 31, 2024
pulisher
May 30, 2024

Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex

May 30, 2024
pulisher
May 30, 2024

BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks

May 30, 2024
pulisher
May 30, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India

May 30, 2024
pulisher
May 29, 2024

Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily

May 29, 2024
pulisher
May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India

May 29, 2024
pulisher
May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com

May 29, 2024
pulisher
May 28, 2024

BioLineRx Q1 Success with APHEXDA® Growth - TipRanks

May 28, 2024
pulisher
May 28, 2024

Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

May 28, 2024
pulisher
May 28, 2024

Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News

May 28, 2024
pulisher
May 25, 2024

BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks

May 25, 2024
pulisher
May 24, 2024

BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com

May 24, 2024
pulisher
May 24, 2024

Ratios Reveal: Breaking Down Bioline Rx Ltd ADR (BLRX)'s Financial Health – DWinneX - The Dwinnex

May 24, 2024
pulisher
May 24, 2024

Examining Bioline Rx Ltd ADR (BLRX) more closely is necessary – US Post News - US Post News

May 24, 2024

Bioline Rx Ltd Adr (BLRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
자본화:     |  볼륨(24시간):